Page 1

OptiScan ASX Announcement 29 January 2021 Imaging Limited ABN 81 077 771 987 APPENDIX 4C QUARTERLY ACTIVITIES & CASHFLOW REPORT QUARTER ENDED 31 DECEMBER 2020 Melbourne , Australia , 29 JANUARY 2021 : Australian medical technology company Optiscan Imaging Limited ( ASX : OIL ) ( Optiscan or the Company ) , a leader in medical technology using confocal laser endomicroscopy , is pleased to release its Appendix 4C - Quarterly Cashflow report and business update for the quarter ended 31 December 2020 ( Quarter ) . All financial results are in Australian dollars and are unaudited . Highlights for the Quarter • Obtained written feedback from the United States Food and Drug Administration ( FDA ) and held a subsequent follow - up call with the FDA indicating Optiscan's 510 ( k ) pathway remains on track for the use of its InVivage ™ device in Oral Cancer Screening and / or Surgery . • • • • • Completed Tranche 2 of the Capital raising announced during the September 2020 quarter with receipt of $ 7.4m in October 2020. Shareholder ratification of the placement and approval of the granting of options pursuant to the placement took place at the Company's General Meeting in November 2020 . Commenced third party independent testing for the InVivage ™ device required for FDA 510 ( k ) clearance . Received the first payment pursuant to the BioMedTech Horizons Program grant to support the University of Melbourne's Melbourne Dental School trial , including funds of $ 180k retained by Optiscan . Entered into a distribution agreement with J & H Technology Co Ltd for the distribution of the FIVE2 ( ViewnVivo ) pre - clinical device in Taiwan . Registration of the CONVIVOⓇ and the Sterile Sheath ( which acts as a sterile barrier between the probe of the CONVIVOⓇ and the tissue in the brain ) on the Australian Register of Therapeutic Goods enabling those devices to be lawfully supplied for use in Neurosurgery in Australia . • Receipt of ethical approval from the Melbourne Health Human Research Ethics Committee for the Breast Cancer Surgical Margin Assessment Trial to take place at Royal Melbourne Hospital , Frances Perry House and the Epworth Hospital . • Cash Flows from Operating Activities of ( $ 409k ) for the Quarter and ( $ 176k ) for the 6 months to 31 December 2020 . Developments Post End of Quarter • Receipt of orders from Carl Zeiss Meditec AG ( CZM ) for approx . $ 350k . • Award of Federal Government Entrepreneurs ' Programme - Growth Grant with matched funding of $ 20k to support the engagement of expert advisers for the development of a United States market entry strategy for InVivage ™ . Phone ( 613 ) 9538 3333 Website www.OptiScan.com PO Box 1066 , Mt Waverley MDC VIC 3149 Australia